Pharmacoeconomics has moved from an academic discipline to an operational imperative in the pharmaceutical industry. Health technology assessment bodies, payers, and governments across the globe now require economic evidence to support pricing and reimbursement decisions. For the pharmaceutical CEO, understanding how to build and deploy pharmacoeconomics capabilities is not optional. It is central to commercial success in every major market.
This guide addresses the business operations dimensions of pharmacoeconomics for pharma CEOs, covering organizational design, evidence generation strategy, market access integration, and the executive decision-making frameworks that determine whether economic evidence translates into commercial value.
The Strategic Importance of Pharmacoeconomics
Pharmacoeconomics studies the cost and outcome tradeoffs of pharmaceutical interventions. It includes cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis, and budget impact modeling. These analyses are used by payers, health technology assessment bodies, and formulary committees to decide whether to cover a drug, at what price, and for which patient populations.
The Payer Landscape Has Changed
The era of payers accepting clinical trial data alone as justification for premium pricing is largely over in developed markets. In the United Kingdom, the National Institute for Health and Care Excellence requires cost-effectiveness evidence for virtually all new drugs. In Germany, the Institute for Quality and Efficiency in Health Care assesses added benefit relative to appropriate comparators. In the United States, while formal HTA is less centralized, pharmacy benefit managers and integrated delivery networks increasingly use cost-effectiveness benchmarks to inform formulary decisions.
CEOs who do not understand these assessment frameworks risk launching drugs that cannot achieve sustainable pricing or access, regardless of their clinical merit. Pharmacoeconomic evidence that has been developed and validated in parallel with clinical development is far more persuasive than evidence assembled reactively after a coverage rejection.
Building Internal Pharmacoeconomics Capability
The decision of whether to build internal health economics and outcomes research capacity versus relying primarily on external consultants has significant operational implications. Organizations with strong internal HEOR teams can develop economic models earlier in development, engage more proactively with payer advisory boards, and respond more quickly to coverage challenges.
The optimal model for most mid-sized to large pharmaceutical companies combines a core internal team with strategic use of academic partnerships and specialist consultants. The internal team sets the economic modeling strategy, manages key external relationships, and ensures that HEOR activities are aligned with development and commercial timelines. External partners provide specialized modeling expertise, independent validation, and geographic reach.
Integrating Pharmacoeconomics into Development Strategy
The most operationally mature pharmaceutical companies integrate health economics into development decisions from Phase II onwards. This means that endpoint selection, data collection, comparator choice, and trial design are all informed by an understanding of what payers will require to justify coverage and pricing.
Early HTA Engagement
CEOs should champion early engagement with health technology assessment bodies as a strategic investment. The FDA’s parallel review program with CMS, the EMA’s parallel scientific advice mechanism with EUnetHTA, and direct scientific advice from national HTA bodies like NICE and IQWIG are available to companies willing to invest the time and resources.
Early HTA engagement reveals what clinical and economic evidence will be required for positive reimbursement decisions and allows companies to design their development programs accordingly. Companies that wait until after regulatory approval to engage with payers and HTA bodies consistently face slower access, lower prices, and greater restrictions than those that engage proactively.
Real-World Evidence Strategy
Real-world evidence has become an increasingly important complement to clinical trial data in pharmacoeconomic submissions. Payers and HTA bodies often have concerns about whether clinical trial populations and outcomes are representative of real-world use. Real-world evidence from registries, electronic health records, and claims databases can address these concerns and support pricing and access negotiations.
CEOs should ensure that real-world evidence strategies are developed as part of integrated evidence plans, not as afterthoughts. This requires investment in data partnerships, epidemiology expertise, and the regulatory and analytical capabilities needed to generate credible real-world evidence.
According to McKinsey on pharmaceutical market access, companies that integrate health economics into early development decisions achieve faster market access and more sustainable pricing than those that treat it as a late-stage commercial activity.
Market Access Operations
Market access is the organizational function responsible for ensuring that approved drugs reach patients at commercially viable prices. It encompasses pricing strategy, reimbursement submissions, payer contracting, and access program management. CEOs who treat market access as a subset of sales and marketing underestimate its strategic importance.
Pricing Strategy in a Global Context
Global pricing decisions have become increasingly complex as reference pricing mechanisms create direct linkages between national prices. A price set in Germany can influence pricing negotiations in a dozen other European markets. A US price, while nominally independent of global markets, increasingly faces scrutiny in the context of international reference pricing debates.
CEOs must develop global pricing strategies that account for these interdependencies. This requires scenario modeling of different price points across key markets, understanding of each market’s reference pricing rules, and careful sequencing of country launches to maximize global price realization.
Managed entry agreements, risk-sharing arrangements, and outcomes-based contracts are increasingly common tools for bridging the gap between manufacturer pricing expectations and payer willingness to pay. CEOs should ensure their organizations have the contracting, data, and operational infrastructure needed to implement and manage these arrangements effectively.
Formulary and Coverage Management
In the United States, formulary management is an ongoing operational activity throughout a drug’s commercial life. Pharmacy benefit managers negotiate formulary placement, and unfavorable formulary positions, including coverage tiers that require prior authorization or step therapy, can significantly reduce patient access and commercial performance.
CEOs should ensure that managed care teams have the economic evidence, relationship capital, and analytical capabilities needed to negotiate favorable formulary positions. Value frameworks and budget impact models that demonstrate a drug’s economic value from the payer’s perspective are essential tools in these negotiations.
For a broader overview of pharmaceutical business operations systems, the pharma operations checklist provides a structured framework for assessing organizational readiness across key operational domains.
Outcomes Research and Post-Market Evidence
The evidence generation obligation does not end at regulatory approval. Payers and HTA bodies increasingly require companies to generate and submit post-market evidence demonstrating that clinical trial outcomes are replicated in real-world settings.
Patient Registries and Observational Studies
Patient registries are important tools for generating post-market evidence. They provide longitudinal follow-up of real-world patient populations, enable subgroup analyses that are not feasible in clinical trials, and support comparative effectiveness research. CEOs should evaluate registry investments not only against their direct evidence generation value but also against their relationship value with physician communities and patient advocacy organizations.
Observational studies using claims data, electronic health records, and linked databases provide complementary evidence to registry data. These studies can be conducted relatively quickly and at lower cost than prospective registries, making them valuable for addressing specific evidence gaps or payer questions.
Generating Evidence for Value-Based Contracts
Outcomes-based contracts require systematic evidence generation to function. If a company promises to rebate a portion of revenue based on patient outcomes, it must have the data infrastructure to measure those outcomes reliably. CEOs should ensure that value-based contract commitments are matched by genuine data collection and analytics capabilities.
This is an area where many companies have made commitments that exceeded their operational capabilities. The reputational and financial consequences of failing to deliver on value-based contract commitments are significant, so CEOs should be realistic about operational readiness before entering into these arrangements.
Organizational Design for Pharmacoeconomics and Market Access
How the pharmacoeconomics and market access functions are organized within the pharmaceutical company has significant implications for their effectiveness.
Positioning HEOR Within the Organization
Health economics and outcomes research functions are positioned differently across pharmaceutical companies. Some place HEOR within medical affairs, emphasizing its scientific nature and connections to clinical development. Others position it within commercial operations or market access, emphasizing its role in supporting pricing and reimbursement. Still others maintain HEOR as a standalone function reporting directly to the Chief Medical Officer or Chief Commercial Officer.
The optimal organizational structure depends on the company’s portfolio, commercial model, and strategic priorities. What matters most is that HEOR has clear mandates, sufficient resources, and strong working relationships with both clinical development and commercial functions.
Talent and Capability Development
Health economists, outcomes researchers, and market access specialists require a distinctive blend of scientific training, economic methodology, and commercial acumen. Building and retaining this talent requires competitive compensation, clear career pathways, and investment in professional development.
CEOs should treat HEOR and market access talent as a strategic asset, not simply a technical resource. The professionals who can design compelling economic models, engage credibly with payer and HTA audiences, and connect evidence to commercial strategy are rare and valuable.
For operational insights specific to precision medicine development, where pharmacoeconomics is particularly complex, pharma precision medicine operations explores the unique challenges of value demonstration for targeted therapies.
CEO Leadership in the Value Demonstration Era
The pharmaceutical CEO’s role in pharmacoeconomics extends beyond organizational design and resource allocation. It includes setting a cultural and strategic tone that values evidence integrity, authentic engagement with payers, and honest communication about where a drug’s value is strong and where it has limitations.
CEOs who oversell economic evidence, underinvest in post-market evidence generation, or treat market access as purely a negotiation problem rather than an evidence problem undermine their organizations’ long-term credibility with payers and HTA bodies. The payer landscape has developed sufficient analytical sophistication to recognize when economic models are more advocacy than analysis.
The companies that build lasting competitive advantages in pharmacoeconomics are those whose CEOs understand that genuine value demonstration, grounded in rigorous evidence and honest communication, is the only sustainable strategy in an era of universal scrutiny over pharmaceutical pricing and access.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.